0
     

Report Added
Report already added
Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Drugs In Development, 2022, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 7, 7, 1, 8 and 4 respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchiectasis - Overview
Bronchiectasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchiectasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchiectasis - Companies Involved in Therapeutics Development
Bronchiectasis - Drug Profiles
Bronchiectasis - Dormant Projects
Bronchiectasis - Discontinued Products
Bronchiectasis - Product Development Milestones
Featured News & Press Releases
May 17, 2022: Insmed presents new data on brensocatib at American Thoracic Society 2022 International Conference
Apr 07, 2022: Renovion provides regulatory update and initiation of clinical program in non-CF bronchiectasis
Feb 22, 2022: Armata Pharmaceuticals announces clearance of investigational new drug application to initiate phase 2 clinical trial of AP-PA02 in non-cystic fibrosis bronchiectasis
Sep 21, 2021: Renovion and the COPD Foundation launch COPD and bronchiectasis development partnership to address unmet patient need
Dec 02, 2020: Insmed announces initiation of phase 3 ASPEN study of brensocatib in patients with bronchiectasis
Nov 15, 2020: SolAeroMed provides update on Phase II trial of S1226
Nov 13, 2020: Insmed receives priority medicines (PRIME) designation from European Medicines Agency (EMA) for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
Sep 30, 2020: Insmed highlights progress across portfolio and outlines growth strategy on brensocatib at R&D Day
Sep 07, 2020: New England Journal of Medicine publishes positive results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis
Jun 24, 2020: Positive Results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis presented at ATS Virtual Clinical Trials Session
Jun 08, 2020: Insmed receives FDA breakthrough therapy designation for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
May 20, 2020: Insmed to showcase new brensocatib data at American Thoracic Society virtual clinical trials session
Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bronchiectasis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bronchiectasis - Dormant Projects, 2022
Bronchiectasis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Bronchiectasis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM